Intravitreal bevacizumab has initial clinical benefit lasting eight weeks in eyes with neovascular age-related macular degeneration by P William Conrad, David N Zacks, Mark W Johnson

“…P William Conrad, David N Zacks, Mark W JohnsonDepartment of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan, USAPurpose: To determine whether the effect of a single initial intravitreal injection of bevacizumab for neovascular age-related macular degeneration (AMD) persists for 8 weeks.Methods: We reviewed the records of 25 consecutive patients with neovascular AMD treated with intravitreal bevacizumab. …”
Get full text

Exploring Anatomy Coursework and Perceptions of Occupational Therapy Students: A Survey Study by Ashleigh Giles, William Conrad, Dianna Lunsford, Kristin A. Valdes

Evaluation of a point-of-care immunoassay test kit 'StrongStep' for cryptococcal antigen detection. by Edward Mpoza, Liliane Mukaremera, Didas Atwebembere Kundura, Andrew Akampurira, Tonny Luggya, Kiiza Kandole Tadeo, Katelyn A Pastick, Sarah C Bridge, Lillian Tugume, Reuben Kiggundu, Abdu K Musubire, Darlisha A Williams, Conrad Muzoora, Elizabeth Nalintya, Radha Rajasingham, Joshua Rhein, David R Boulware, David B Meya, Mahsa Abassi

Get full text